
Biote Corp (BTMD) Stock Forecast & Price Target
Biote Corp (BTMD) Analyst Ratings
Bulls say
Biote is facing pandemic-related risks that could potentially disrupt its operations and harm revenue. Additionally, with a business model that is subject to wage increases and other inflationary pressures, the company may struggle to pass on price increases to patients without negatively impacting business metrics. Furthermore, its limited operating history poses risks for potential production increases and future growth.
Bears say
Biote is experiencing challenges with acquisitions and retention of new clinics, as well as a slowdown in new clinic productivity due to a recall of certain hormone pellets, resulting in lower procedure revenues and a decrease in net income. The company also faces intense competition and risks associated with expanding into new markets, regulatory compliance, and dependence on key personnel and outsourcing facilities. These factors, coupled with ongoing legal expenses, lead to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Biote Corp and is not a guaranteed prediction by Public.com or investment advice.
Biote Corp (BTMD) Analyst Forecast & Price Prediction
Start investing in Biote Corp (BTMD)
Order type
Buy in
Order amount
Est. shares
0 shares